02064nas a2200301   4500000000100000008004100001260001000042653001400052653001300066653001100079653001400090653001400104653002500118653001600143653001400159653001900173100001000192700001300202700001200215700001100227700001700238700001600255245009800271856006300369300001600432520128900448022002501737       2024                            d  bWiley10aPsoriasis10aBarriers10aAccess10aDisparity10aBiologics10aSocioeconomic status10arural areas10aEthnicity10askin of colour1 aWan V1 aHabibi A1 aMija LA1 aAbdi P1 aSelvakumar R1 aMukovozov I00aDisparities and barriers to the access of biologics in moderate‐to‐severe adult psoriasis  uhttps://onlinelibrary.wiley.com/doi/epdf/10.1111/ijd.17236  a1293–13013 a<p>Psoriasis is a chronic, relapsing inflammatory skin disorder that is associated with substantial physical and psychosocial comorbidity. Although biologic agents have offered transformative therapeutic advantages to those unresponsive to traditional treatments, data from recent literature indicate significant undertreatment of certain populations, highlighting potential barriers to access. This review aims to comprehensively elucidate barriers to biological therapy, addressing a recognized gap in the current literature. A search was conducted using MEDLINE, Embase, and Web of Science to investigate the obstacles and disparities that prevent access to biologic treatments in biologic‐naïve psoriatic patients. Emergent themes were then systematically categorized into five primary domains: patient‐level, prescriber‐level, medicine‐level, organizational‐, and external environment‐level factors. Our results demonstrate pronounced barriers and disparities encompassing increased age, race, socioeconomic status, rural location, cost and insurance, and insufficient knowledge that may hinder access to biologic treatments among psoriatic patients. Further research on how these barriers can be effectively addressed is needed to optimize treatment outcomes.</p>
  a0011-9059, 1365-4632